• Does an SVR to Therapy for HCV-associated Cirrhosis Reduce Portal Pressure?

Does an SVR to Therapy for HCV-associated Cirrhosis Reduce Portal Pressure?

A sustained virologic response (SVR) to all-oral therapy in patients with hepatitis C virus (HCV)-associated cirrhosis significantly reduces the hepatic venous pressure gradient (HVPG), researchers report in the November issue of Gastroenterology. Nevertheless, almost 80% of patients maintain significant portal hypertension and have a continued risk of decompensation. In patients with compensated

Read more
  • Can Direct-acting Antivirals Treatment of HCV Reactivate Herpesvirus Infection?

Can Direct-acting Antivirals Treatment of HCV Reactivate Herpesvirus Infection?

Researchers report reactivation of herpesvirus in 10 patients with hepatitis C virus (HCV) infection treated with direct-acting antiviral (DAA) agents in the November issue of Clincial Gastroenterology and Hepatology. Christie Perelló et al performed a case series analysis of reactivation of herpesvirus in patients with HCV infection treated with DAA

Read more

Advances in PSC, NAFLD, and Liver Transplantation for Patients with HCV Infection reported at International Liver Congress

A chemical cousin of an existing drug shows promise for patients with primary sclerosing cholangitis (PSC), a larger waistline increases risk for severe nonalcoholic fatty liver disease (NAFLD), and livers from hepatitis C virus (HCV)-infected donors are safe for transplant into HCV-infected recipients were all among the exciting findings reported

Read more
  • As Incidence and Deaths from Other Cancers Decrease, Liver Cancer Increases in US

As Incidence and Deaths from Other Cancers Decrease, Liver Cancer Increases in US

Deaths from almost all cancers in the United States decreased from 1975 to 2012—except for liver cancer. In the Annual Report to the Nation on the Status of Cancer, 1975–2012, published online by the National Cancer Institute, A. Blythe Ryerson et al report that the overall cancer death rates for

Read more
  • Gilead Sells Sofosbuvir to Egypt for About $10 per Pill

Gilead Sells Sofosbuvir to Egypt for About $10 per Pill

In Egypt, pharmaceutical companies are testing a complicated deal to sell hepatitis C drugs at a fraction of their usual cost while imposing tight restrictions intended to protect lucrative markets in the West. According to the New York Times, Gilead Sciences Inc. is selling its sofosbuvir to the Egyptian government

Read more
  • Bradycardia After Sofosbuvir and Daclatasvir in 2 Patients Receiving Amiodarone

Bradycardia After Sofosbuvir and Daclatasvir in 2 Patients Receiving Amiodarone

Two patients receiving treatment with amiodarone developed bradycardia within 2 hours after taking sofosbuvir and daclatasvir  for hepatitis C, researchers report in the November issue of Gastroenterology. Patients treated with amiodarone should be continuously monitored within the first 48 hours after receiving these hepatitis C drugs, say the authors of the Brief Report. Sofosbuvir and

Read more
  • Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Improving Outcomes of Patients With Fibrosing Cholestatic Hepatitis C

Sofosbuvir-based regimens, with or without daclatasvir, greatly improve the clinical status of patients who develop fibrosing cholestatis hepatitis (FCH) after liver transplantation for hepatitis C virus (HCV) infection, and most of the patients achieve a sustained virologic response (SVR), researchers report in the November issue of Clinical Gastroenterology and Hepatology. These results

Read more
  • Special Issue: Managing Patients With Liver Disease

Special Issue: Managing Patients With Liver Disease

A special issue of Clinical Gastroenterology and Hepatology is dedicated to the clinical management of hepatic disorders, including nonalcoholic fatty liver disease (NAFLD), viral hepatitis, autoimmune hepatitis, and primary sclerosing cholangitis (PSC). The issue comprises 14 review articles that aim to present clinicians with evidence-based guidance and expert opinions on management of patients with liver

Read more
  • Public Health Officials Call for Wider Access to HCV Drugs

Public Health Officials Call for Wider Access to HCV Drugs

Experts from the Public Health Service and President Obama’s Advisory Council on HIV/AIDS are calling on federal and state Medicaid officials to widen access to prescription drugs that could cure tens of thousands of people with hepatitis C virus (HCV) infection. They say restrictions on the drugs imposed by many

Read more

Cheap Allergy Drug Prevents HCV Infection of Hepatocytes

An over-the-counter allergy drug may be repurposed to treat patients with hepatitis C, researchers show. Chlorcyclizine, which costs about $0.50 a tablet, could offer a low-cost alternative or addition to treatment for patients with hepatitis C virus (HCV) infection. Direct-acting antiviral therapies can cure hepatitis C, but their high cost—which

Read more